Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1752W HIGH $2.71
Volume
31.09 K
Value Traded
14.86 M
Short % Float
-
-1.28%Week
-21.03%1 Month
-14.09%3 Month
+9.22%6 Month
-53.66%5 Year
-67.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
173.16 M
EPS (TTM)
-0.61
P/E Ratio
-
Ent. Value
164.86 M
Total Shares
111.72 M
Float Shares
-
Insiders
-
Institutions
0.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IPHA Catalyst Timeline
Dated clinical, regulatory and corporate events for Innate Pharma S.A.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Innate Pharma S.A.
435Total events
20Upcoming
76Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
Innate Pharma reported first half 2026 business update and financial results
▲Partnership / LicenselacutamabCorporate
Closing of Sobi partnership transaction, triggering USD 75 million upfront payment
cutaneous T-cell lymphomasource ↗
▲Milestone PaymentlacutamabCorporate
USD 75 million upfront payment triggered by transaction closing
T-cell lymphomasource ↗
▲Trial InitiationlacutamabTrial
Initiation of TELLOMAK-3 confirmatory Phase 3 study
cutaneous T-cell lymphomasource ↗
▲Milestone PaymentCorporate
Sobi to pay Innate USD 75 million upon partnership becoming effective
●R&D DayPresentation
Innate Pharma fireside chat at H.C. Wainwright 28th Annual Global Investment Conference
●Management ChangeCorporate
Appointment of Markus Jensen as Chief Medical Officer, effective September 1, 2026
▲Partnership / LicenselacutamabCorporate
Sobi entered strategic partnership with Innate to enable TELLOMAK-3 confirmatory Phase 3 study
cutaneous T cell lymphoma (CTCL)source ↗
▲Partnership / LicenselacutamabCorporate
Innate Pharma entered strategic partnership with Sobi to license lacutamab in T-cell lymphoma
T-cell lymphomasource ↗
▲Enrollment CompleteIPH4502Trial
Enrollment completed in dose escalation of IPH4502-101 study
advanced solid tumorssource ↗
▲Enrollment CompleteIPH4502Trial
Completion of dose-escalation and backfill enrollment in Phase 1 study of IPH4502
multiple tumor types known to express Nectin-4source ↗
●ATM ProgramCorporate
Balance available under April 2023 At-The-Market program remains at $75 million
◆Enrollment UpdateIPH4502Trial
Approaching completion of enrollment in Phase 1 dose escalation and backfill cohorts for IPH4502
solid tumorssource ↗
◆Oral PresentationPresentation
Innate Pharma to participate in D. Boral Capital Global Conference
▲Oral PresentationIPH5201Presentation
Interim results from MATISSE Phase 2 trial of IPH5201 presented at AACR 2026
resectable non-small cell lung cancersource ↗
▲Interim AnalysisIPH5201Trial
Pre-planned interim analysis of MATISSE trial on 40 patients
resectable non-small cell lung cancersource ↗
◆Enrollment UpdateIPH5201Trial
MATISSE trial continues to recruit patients with PD-L1≥1% tumors
resectable non-small cell lung cancersource ↗
▲Interim AnalysisIPH5201Trial
Pre-planned interim analysis on 40 patients shows higher pCR rates
resectable non-small cell lung cancersource ↗
▲Enrollment UpdateIPH5201Trial
Study continues to recruit patients with PD-L1>=1% tumors
resectable non-small cell lung cancersource ↗
◆Oral PresentationPresentation
Innate Pharma to present at AACR 2026 Oncology Industry Partnering Event
◆Oral PresentationPresentation
Innate Pharma to participate in Kempen Life Sciences Conference
◆Oral PresentationPresentation
Innate Pharma to participate in Leerink Partners Global Healthcare Conference 2026 fireside chat
▲Oral PresentationIPH5201Presentation
Encouraging results from MATISSE Phase 2 trial presented at AACR Annual Meeting 2026
neoadjuvant lung cancersource ↗
▼Program DiscontinuationIPH6401DiscontinuedCorporate
Sanofi announced deprioritization of SAR'514 (IPH6401)
▲Interim AnalysisIPH5201Trial
Encouraging interim analysis results from MATISSE Phase 2 study presented at AACR 2026
resectable NSCLCsource ↗
▲IND ClearancelacutamabIND
FDA clearance to proceed with confirmatory Phase 3 trial TELLOMAK 3
cutaneous T-cell lymphomas (CTCL)source ↗
◆R&D DaylacutamabPresentation
Analyst and investor event on lacutamab
cutaneous T-cell lymphoma (CTCL)source ↗
●Oral PresentationlacutamabPresentation
KOL event on lacutamab with updates on Phase 3 trial and regulatory pathway
cutaneous T-cell lymphomas (CTCL)source ↗
◆Enrollment CompleteIPH4502Trial
Enrollment completion of dose escalation part
advanced solid tumorssource ↗
◆Quarterly UpdateCorporate
First Half 2025 Financial Results and Business Update Conference Call
◆Oral PresentationPresentation
Innate Pharma CEO and COO to participate in BTIG Virtual Biotechnology Conference fireside chat
◆Oral PresentationPresentation
H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference
◆Poster PresentationIPH6501Presentation
Poster presentation of IPH6501 antitumor characterization at EHA 2025
relapsed and/or refractory Non-Hodgkin Lymphomasource ↗
◆Poster PresentationIPH6401DiscontinuedPresentation
Online publication of SAR'514 IPH6401 abstract at EHA 2025
Multiple Myelomasource ↗
◆Oral PresentationPresentation
Goldman Sachs 46th Annual Global Healthcare Conference fireside chat
◆Poster PresentationlacutamabPresentation
Long-term follow-up and translational data from TELLOMAK Phase 2 trial in mycosis fungoides
mycosis fungoidessource ↗
◆Poster PresentationIPH4502Presentation
Phase 1 study of IPH4502 as single agent in advanced solid tumors
advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How IPHA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | Lacutamab | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$130M
Pipeline Value
Fair Value
Valuation Signal
7
Drugs Scored
0.8x
rNPV / MCap
Top 28%
Micro Cap(rank 185 of 658)
Percentile Rank
Innate Pharma S.A. carries a moderate pipeline score (45/100), with $1.5B risk-adjusted pipeline value, led by IPH2101 in Smoldering Multiple Myeloma (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPH5201 Small moleculeNCT05742607 | Non Small Cell Lung Cancer | Phase 2 | RECRUITING | 70 | Jun 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every IPHA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IPH5201 | resectable non-small cell lung cancer (NSCLC) | Phase 2 | 2026-04-20 | p CR rate PD L1 1 percent: 35.7%; p CR rate PD L1 50 percent: 50%Read More | Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IPHA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.3 % | 839.00 K | 184.05 K |
IPHA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IPHA ranks across every disease it competes in
Competitive Position is a premium feature
See how IPHA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIPHA News
IPHAInnate Pharma Reports First Half 2026 Business Update and Financial Results
Innate Pharma SA has released its consolidated financial results for the first half of 2026. The company highlighted its strategic partnership with Sobi and emphasized the importance of 2026 as a year of execution. CEO Jonathan Dickinson noted the strengthening of the company's financial position.
Read more →IPHASobi and Innate announce partnership is now effective following completion of closing conditions
Sobi and Innate Pharma have announced that their strategic partnership is now effective after meeting closing conditions. This partnership will facilitate the initiation of the TELLOMAK-3 Phase 3 study for lacutamab in cutaneous T-cell lymphoma, aiming for accelerated approval in Sézary syndrome. Sobi will pay Innate $75 million and has the potential for further milestone payments.
Read more →IPHAInnate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
Innate Pharma has confirmed that its strategic partnership with Sobi is now effective after fulfilling necessary closing conditions, including antitrust waiting periods. This partnership, initially announced on August 10, 2026, involves the licensing of lacutamab for T-cell lymphoma. The transaction includes a significant financial component of USD 75 million.
Read more →IPHAInnate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
Innate Pharma SA has announced a conference call scheduled for September 17, 2026, to discuss its financial results for the first half of 2026. The call will feature key executives, including the CEO and Chief Medical Officer, who will provide updates on the company's business and strategic direction. This event reflects the company's commitment to transparency and stakeholder engagement.
Read more →IPHAInnate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Innate Pharma SA has announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York. Members of its executive team will engage in a fireside chat and hold one-on-one meetings with investors. This event underscores the company's commitment to investor relations and visibility in the biotech sector.
Read more →IPHA▼ -14%on this news
Innate Pharma Announces Conference Call and Webcast
Innate Pharma has announced a conference call and webcast to engage with stakeholders. This initiative reflects the company's commitment to transparency and effective communication. Details regarding the timing and agenda of the call were not provided in the announcement.
Read more →IPHA▲ +28.3%on this news· ran to +47% by day 3
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Sobi has entered a strategic partnership with Innate Pharma to initiate the TELLOMAK-3 Phase 3 study for lacutamab in cutaneous T-cell lymphoma. This collaboration aims to support an accelerated approval filing for S zary syndrome, a subtype of CTCL. Sobi will gain exclusive commercialization rights upon potential approval, with further development milestones outlined in the agreement.
Read more →IPHA▲ +28.3%on this news· ran to +47% by day 3shared move
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Innate Pharma announced plans to initiate the TELLOMAK-3 Phase 3 study of lacutamab for cutaneous T-cell lymphoma, pending the completion of a partnership with Sobi. Additionally, Markus Jensen has been appointed as the new Chief Medical Officer, effective September 1, 2026, succeeding the previous officer. This strategic move aims to bolster the company's leadership and research efforts.
Read more →IPHA▲ +28.3%on this news· ran to +47% by day 3shared move
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma has formed a strategic partnership with Sobi to advance the TELLOMAK-3 Phase 3 study for lacutamab in cutaneous T-cell lymphoma. This collaboration is crucial for seeking accelerated approval of the drug for Sézary syndrome, a specific subtype of CTCL. The partnership aims to enhance the development and potential market entry of lacutamab.
Read more →IPHAInnate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Innate Pharma will participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference. This engagement underscores the company's focus on bladder cancer research and its commitment to advancing discussions in the field. The conference provides a significant opportunity for Innate Pharma to showcase its expertise and insights.
Read more →IPHAInnate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Innate Pharma has announced the completion of enrollment in the Phase 1 dose escalation study of its novel Nectin-4 exatecan antibody-drug conjugate, IPH4502. The study, which includes 76 patients, aims to guide dose optimization for specific tumor types. Preliminary data from the study is anticipated by the end of the year.
Read more →IPHA▼ -7.1%on this news
Outcome of Innate Pharma’s 2026 Annual General Meeting
Innate Pharma SA held its Annual General Meeting on May 21, 2026, in Marseille, where all shareholder resolutions were voted on. A total of 94 votes were cast, representing a quorum of 37,136%. The results and related documents will be available on the company's website. Innate Pharma continues to develop innovative immunotherapies for cancer.
Read more →IPHA▼ -9.8%on this newsshared move
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Innate Pharma announced its participation in the Jefferies Global Healthcare Conference 2026, where its executive team will engage in one-on-one investor meetings. The company focuses on developing immunotherapies for cancer patients and has a portfolio of promising assets. This participation highlights Innate's commitment to advancing its innovative therapies.
Read more →IPHAInnate Pharma Reports First Quarter 2026 Business Update and Financial Results
Innate Pharma has released its business update and financial results for the first quarter of 2026. The report includes insights into the company's performance and strategic direction. However, specific details regarding financial metrics or operational highlights were not disclosed in the article.
Read more →IPHANumber of shares and voting rights of Innate Pharma as of
Innate Pharma has released information as of April 16, 2026, regarding its total number of shares outstanding and voting rights. The total number of shares outstanding is reported to be 93,934,210, including ordinary and preferred shares. The company also noted its theoretical and exercisable voting rights, which are vital for shareholder engagement. Innate Pharma continues to develop innovative therapeutics for cancer treatment and collaborates with prominent firms like Sanofi and AstraZeneca.
Read more →IPHA▲ +7.9%on this news
Innate Pharma announces conference call and webcast for Q1 2026 Business Update
Innate Pharma has announced that it will hold a conference call on May 13, 2026, to update stakeholders on business progress for the first quarter of the year. The call will feature several key executives, including the CEO and Chief Medical Officer, indicating a thorough approach to communication. The company is engaged in developing immunotherapies for cancer and has a portfolio that includes several promising therapeutic candidates. This update reflects Innate Pharma's ongoing commitment to transparency and innovation in the biopharma space.
Read more →IPHAInnate Pharma to participate in the D. Boral Capital Global Conference
Innate Pharma SA announced its participation in the D. Boral Capital Global Conference, where its executive team will engage in one-on-one investor meetings. The company develops immunotherapies for cancer and is actively advancing several differentiated potential therapies. This participation underscores the company's commitment to connecting with investors and showcasing its innovative pipeline. Innate Pharma is known for its collaborations with leading biopharmaceutical companies.
Read more →IPHAInnate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Innate Pharma announced that interim results from the MATISSE Phase 2 study of IPH5201 will be presented at the AACR Annual Meeting 2026. The study evaluates IPH5201 in combination with durvalumab and chemotherapy for resectable non-small cell lung cancer (NSCLC). Results show higher pathological complete response rates, particularly in patients with PD-L1 positive tumors.
Read more →IPHAINNATE PHARMA TO PRESENT MATISSE PHASE 2 INTERIM RESULTS OF IPH5201 IN CLINICAL TRIALS PLENARY SESSION AT AACR 2026
Innate Pharma announced the presentation of interim results from the MATISSE Phase 2 study of IPH5201 at the AACR Annual Meeting 2026. The study evaluates IPH5201 in combination with durvalumab and chemotherapy for patients with resectable non-small cell lung cancer (NSCLC). Results indicate that the combination led to higher pathological complete response rates compared to benchmarks. The presentation will further detail the effectiveness of dual inhibition in enhancing anti-tumor immunity.
Read more →IPHAInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
Innate Pharma will hold its Annual General Meeting (AGM) on May 21, 2026, at its headquarters in Marseille. The meeting will include a guided tour of the company's laboratories and will be broadcast live. Shareholders must register their shares by May 14, 2026, to attend. Written questions must be submitted by May 15, 2026.
Read more →About Innate Pharma S.A.
BIOPHARMAWATCH ELITE PLUS
Trade the next IPHA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime